Loading...

CABA CABALETTA BIO INC US FDA Inspections 8-K Filing

CBLT

CB

CABALETTA BIO INC

(CABA)

2025 8-K

Show Summary

Summary

Equity Offerings

Management Changes

Increase in authorized shares

Compensatory Arrangements o...

Product Expansion

Financial Results

Clinical Data Update

Clinical Data Update

Financial Update

Clinical Data Update

Q3 Financial Results

Corporate Update

Lease Amendment

Financial Results and Corpo...

Investor Presentation and P...

Annual Meeting of Stockholders

Financial Results and Corpo...

Financial Results Announcement

FDA Designation Granted

FDA Orphan Drug Designation

Financial Update

Earnings Reports

FDA Clearance for Phase 1/2...

Expansion of Manufacturing ...

Financial Results Announcement

Annual Meeting Approval

Offering Closing

Public Offering

Corporate Presentation and ...

FDA Clearance for Phase 1/2...

Financial Results Announcement

ASGCT Annual Meeting Presen...

Corporate Presentation and ...

Corporate Presentation and ...

Financial Results and Corpo...

Corporate Presentation

External Links:

Cabaletta Bio, Inc. clarified updated clinical data showing the first adult dermatomyositis patient in the RESET-Myositis trial was off all immunosuppressants as of January 8, 2025, and issued a revised press release and corporate presentation.

AI Assistant

CABALETTA BIO INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.